Document is current

Article History

Received: 13 March 2024

Accepted: 14 July 2024

First Online: 30 July 2024

Competing interests

: V.M. reports receiving speaker honoraria and travel support from Amgen, AstraZeneca, Celgene, Roche, Tesaro, and Myelo Therapeutics. H.J.L. reports consultant/advisory role with Roche, Novartis and Sanofi, and honoraria from Roche, GSK, and Sanofi. M.S. reports personal fees from AstraZeneca, personal fees from BioNTech, personal fees from Daiichi Sankyo, personal fees from Eisai, personal fees from Lilly, personal fees from MSD, personal fees from Novartis, personal fees from Pfizer, personal fees from Pierre-Fabre, personal fees from Roche, and personal fees from Seagen outside the submitted work; in addition, M.S. has a patent for EP 2390370 B1: A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent issued and a patent for EP 2951317 B1: A method for predicting the benefit from inclusion of a taxane in a chemotherapy regimen in patients with breast cancer issued. A.S. received honoraria from Roche, Astra Zeneca, Celgene, Pfizer, Amgen, and Novartis. M.U. reports personal fees for lectures and/or consultancy from Abbvie, Amgen, AstraZeneca, Daiji Sankyo, Gilead, GSK, Genzyme, Lilly, Medac, MSD Merck, Myriad Genetics, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi Aventis, Stemline, and Seagen. F.M. received grants and personal fees from Gilead/Immunomedics, as well as personal fees from AstraZeneca, Amgen, CureVac, Celgene, Clovis Oncology, Eisai, Genomic Health, GSK, Janssen-Cilag, Novartis, MSD, Myriad, Pfizer, PharmaMar, Pierre-Fabre, Roche, Seagen, and Tesaro. J.U.B. has received research funding from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Myriad and honoraria for lectures and participation at advisory boards from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche. C.J. has received research funding from Amgen, Roche, and Exact Sciences. He participated in Advisory Boards for AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, Lilly, Gilead, and Daiichi Sankyo. He received honoraria from Amgen, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, TEVA, Eisai, Lilly, Gilead, Daichii Sankyo, and Pierre Fabre. J.H. reports grants from Novartis, Celgene and Hexal, personal fees from Novartis, Lilly, Pfizer, Roche, Abbvie, AstraZeneca, Eisai, Celgene, MSD and Hexal, and travel expenses from Pfizer, Roche, Daichii Sankyo and Celgene. E.S. has received honoraria from Pfizer, Roche, Astra, MSD, Gilead, Daiichi Sankyo, Novartis, Seagen, Lilly and Pierre Fabre. M.R. has received honoraria and/or consultancy fee and/or travel support from: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, and Somatex. T.L. has received honoraria from Amgen, AstraZeneca, MSD, GSK, Novartis, Pfizer, Roche, Clovis, TEVA, Tesaro, Lilly, Gilead, Daichii Sankyo and non-financial support from Roche, Pfizer, MSD, Celgene, Clovis, Daichii Sankyo, Gilead and AstraZeneca; in addition, T.L. participates at advisory boards from Tesaro, Amgen, Myriad, MSD, GSK, Novartis, Pfizer, Roche, Eisai, Lilly, Gilead, and Daichii Sankyo. W.J. reports grants and personal fees from Sanofi-Aventis, Novartis, Lilly, Pfizer, Roche, Chugai, and AstraZeneca. C.D. reports grants from European Commission H2020, grants from German Cancer Aid Translational Oncology, grants from German Breast Group, all to the institution; personal fees from Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca, Merck, Molecular Health, grants from Myriad and Roche to the institution, grants from GBG foundation to the institution; in addition, C.D. has a patent on VMscope digital pathology software with royalties paid, a patent WO2020109570A1 - cancer immunotherapy pending, and a patent WO2015114146A1 and WO2010076322A1- therapy response issued. S.S. and J.R. declare to be GBG Forschungs GmbH employee. GBG Forschungs GmbH received funding for research grants from Abbvie, AstraZeneca, BMS, Daiichi-Sankyo, Gilead, Novartis, Pfizer, and Roche (paid to the institution); other (non-financial/medical writing) from Daiichi-Sankyo, Gilead, Novartis, Pfizer, Roche, and Seagen (paid to the institution). GBG Forschungs GmbH has following royalties/patents: EP14153692.0, EP21152186.9, EP15702464.7, EP19808852.8 and VM Scope GmbH. S.L. declares to be GBG Forschungs GmbH employee (CEO); receive grants from AbbVie, AstraZeneca, Celgene, Daiichi-Sankyo, Immunomedics/Gilead, Molecular Health, Novartis, Pfizer and Roche; honoraria for Advisory board from Abbvie, Amgen, AstraZeneca, BMS, Celgene, DSI, EirGenix, Gilead, GSK, Lilly, Merck, Novartis, Olema, Pfizer, Pierre Fabre, Relay Therapeutics, Roche, Sanofi, and Seagen; honoraria as invented speaker from AstraZeneca, DSI, Gilead, Novartis, Pfizer, Roche, Seage, and Medscape. S.L. reports non-financial interest as advisory role in AGO Kommission Mamma, as principal investigator (Aphinity), as member in AGO, ASCO, DKG, ESMO, and other non-financial interest from AstraZeneca, Daiichi-Sankyo, Immunomedics/Gilead, Novartis, Pfizer, Roche, and Seagen. GBG Forschungs GmbH has the following royalties/patents: EP14153692.0, EP21152186.9, EP15702464.7, EP19808852.8, and VM Scope GmbH. No other potential conflicts of interest relevant to this article were reported.